Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 38 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

0%

0 of 37 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
36(94.7%)
N/A
1(2.6%)
Phase 4
1(2.6%)
38Total
Phase 2(36)
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (38)

Showing 20 of 38 trials
NCT03745300Phase 2Completed

Comparative Evaluation Of 1.2% Atorvastatin and 1.2% Simvastatin Gel Local Drug Delivery And Redelivery In Chronic Periodontitis Subjects With Diabetes Mellitus: A Randomized Controlled Clinical Trial.

Role: lead

NCT03741309Phase 2Completed

Comparison of Clinical Efficacy of a Dentifrice Containing 5% Fluoro Calcium Phosphosilicate to a Dentifrice Containing Calcium Sodium Phosphosilicate on Dentinal Hypersensitivity

Role: lead

NCT03738514Phase 2Completed

Comparison of Efficacy of 5% Fluorocalcium Phosphosilicate Dentifrice and Potassium Nitrate Dentifrice on Dentinal Hypersensitivity

Role: lead

NCT03207698Phase 2Completed

PRF+1% MF for Class II Mandibular Furcation Defects

Role: lead

NCT03204071Phase 2Completed

Locally Delivered Metformin and Aloe Vera for Treatment of Intrabody Defects in Chronic Periodontitis

Role: lead

NCT03204097Phase 2Completed

Local Host Modulating Agents Alendronate & Aloe Vera for Treatment of Furcation Defects in Chronic Periodontitis

Role: lead

NCT03204058Phase 2Completed

Locally Delivered Metformin & Rosuvastatin for Treatment of Intrabony Defects in Chronic Periodontitis

Role: lead

NCT03043196Phase 2Completed

1.2% Rosuvastatin Gel As A Local Agent In Smokers With Chronic Periodontitis

Role: lead

NCT02985099Phase 2Completed

1.2% Rosuvastatin Subgingivally Delivered In Chronic Periodontitis With Type 2 Diabetes Mellitus

Role: lead

NCT02903108Phase 2Completed

Clinical Efficacy of 0.75% Boric Acid Gel in Chronic Periodontitis

Role: lead

NCT02800902Phase 2Completed

Locally Delivered Atorvastatin & Rosuvastatin for Treatment of Furcation Defects in Chronic Periodontitis

Role: lead

NCT02738541Phase 2Completed

Anti-calculus Efficacy of a Dentrifice Containing Sodium Pyrophosphate and Potassium Pyrophosphate in Heavy Calculus Formers

Role: lead

NCT02738515Phase 2Completed

Boric Acid in Degree 2 Furcation Defect

Role: lead

NCT02645227Phase 2Completed

Platelet-rich Fibrin With 1.2% Rosuvastatin in Chronic Periodontitis Treatment

Role: lead

NCT02612792Phase 2Completed

Platelet Rich Fibrin+1.2% Atorvastatin in Treatment of Mandibular Degree II Furcation Defects

Role: lead

NCT02609061Phase 2Completed

Platelet Rich Fibrin+1% Alendronate in Treatment of Mandibular Degree II Furcation Defects

Role: lead

NCT02600520Phase 2Completed

Comparison of Rosuvastatin With Atorvastatin in Chronic Periodontitis

Role: lead

NCT02580331Phase 2Completed

1% Metformin Gel in the Treatment of Class II Furcation Defects

Role: lead

NCT02518152Phase 2Completed

Platelet Rich Fibrin+1% Alendronate in Treatment of Chronic Periodontitis

Role: lead

NCT02516111Phase 2Completed

Comparison of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Chronic Periodontitis Treatment

Role: lead